StreetInsider.com News Articles

BridgeBio reports infigratinib trial data on sleep apnea, ear infections

Wed, 09 Sep 2026 04:00:18 -0400

BridgeBio Pharma (Nasdaq: BBIO) presented exploratory data from its Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, showing trends in sleep apnea and ear infection measures compared to placebo at 52 weeks.

The mean total Apnea-Hypopnea Index increased 10.4% in the infigratinib group versus 49.2% in the placebo group. In children under 8 years old, the index was unchanged in the treatment group compared to a 63.2% increase in the placebo group.

The estimated annualized rate of otitis media was 38% lower in the infigratinib group versus placebo overall, and 47% lower among children under 8 years old.

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Wed, 09 Sep 2026 04:00:00 -0400

- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group; in children younger than 8 years of age, the mean total AHI was unchanged for the oral infigratinib group, versus a 63.2% increase in the placebo group
Reduction in rate of

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Wed, 09 Sep 2026 04:00:00 -0400

- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group; in children younger than 8 years of age, the mean total AHI was unchanged for the oral infigratinib group, versus a 63.2% increase in the placebo group

Reduction in rate of

BridgeBio to present infigratinib data at ESPE meeting in September

Wed, 02 Sep 2026 07:30:18 -0400

BridgeBio Pharma (NASDAQ: BBIO) announced it will present data on oral infigratinib in achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, scheduled for September 8-10 in Marseille, France.

The presentations include one late-breaking oral presentation, two posters, and one e-poster. The late-breaking oral presentation, titled "A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study," is scheduled for September 9 at 10:00 a.m. CEST. Julie Hoover-Fong, M.D., Ph.D., of Johns Hopkins University, will present.

Two posters will be presented by Melita Irving, M.D., of Guy's and St Thomas' NHS Foundation Trust

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

Wed, 02 Sep 2026 07:30:00 -0400

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.

In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia,

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

Wed, 02 Sep 2026 07:30:00 -0400

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.

In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia,

H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Wed, 02 Sep 2026 06:55:45 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $120.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst commented: "This week, BridgeBio presented new analyses from the Phase 3 ATTRibute-CM study of ATTRUBY (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance imaging (CMR) substudy and the open-label extension (OLE) at the European Society of Cardiology (ESC) Congress 2026 held in Munich, Germany. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. In a completer analysis, clinically meaningful improvement from baseline in left ventricular (LV) systolic function was observed in 54% of

BridgeBio to Participate in September Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT
2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT
Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT
Bernstein Insights Healthcare

BridgeBio to Participate in September Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT
2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT
Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT
Bernstein Insights Healthcare

Trump announces nine more pharma firms in drug pricing deals

Mon, 31 Aug 2026 15:16:26 -0400
(Updated - August 31, 2026 3:16 PM EDT)
President Donald Trump announced agreements with nine additional pharmaceutical manufacturers to lower prescription drug prices in line with most-favored-nation (MFN) pricing, according to a White House statement dated August 31, 2026.
The new agreements bring the total number of manufacturers with MFN deals to 26, which the administration says covers 89% of the branded drug market. The nine companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
Under the agreements, all state Medicaid programs will gain access to MFN pricing on products made by the nine companies.

Trump announces nine more pharma firms in drug pricing deals

Mon, 31 Aug 2026 15:16:26 -0400
(Updated - August 31, 2026 3:16 PM EDT)
President Donald Trump announced agreements with nine additional pharmaceutical manufacturers to lower prescription drug prices in line with most-favored-nation (MFN) pricing, according to a White House statement dated August 31, 2026.
The new agreements bring the total number of manufacturers with MFN deals to 26, which the administration says covers 89% of the branded drug market. The nine companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
Under the agreements, all state Medicaid programs will gain access to MFN pricing on products made by the nine companies.

BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho

Mon, 31 Aug 2026 13:59:53 -0400

Mizuho analyst Salim Syed raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $110.00 (from $96.00) while maintaining a Outperform rating.
The analyst comments "BBIO (OP, increasing PT to $110): Story continues to move forward with four potential commercial products by 2H27; Commercial Day 10/8 (potential catalyst). We increase our PT to $110 (from $96) on higher Attruby numbers, post IONS/AZN's (both NC) CARDIO-TTRansform failure. We currently model Attruby at ~$4Bn peak sales in the US (up from ~$3.4Bn), and even this may prove conservative. Recall, BBIO's Commercial Day is on 10/8. One potential scenario, we believe (to be clear,

BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho

Mon, 31 Aug 2026 13:59:53 -0400

Mizuho analyst Salim Syed raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $110.00 (from $96.00) while maintaining a Outperform rating.
The analyst comments "BBIO (OP, increasing PT to $110): Story continues to move forward with four potential commercial products by 2H27; Commercial Day 10/8 (potential catalyst). We increase our PT to $110 (from $96) on higher Attruby numbers, post IONS/AZN's (both NC) CARDIO-TTRansform failure. We currently model Attruby at ~$4Bn peak sales in the US (up from ~$3.4Bn), and even this may prove conservative. Recall, BBIO's Commercial Day is on 10/8. One potential scenario, we believe (to be clear,

BridgeBio's acoramidis shows cardiac reversal data at ESC 2026

Mon, 31 Aug 2026 06:04:00 -0400

BridgeBio Pharma (Nasdaq: BBIO) presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2026, according to a company statement.
Data from a cardiac magnetic resonance imaging (CMR) substudy showed that 54% of acoramidis-treated patients demonstrated clinically meaningful improvement in left ventricular systolic function at Month 30, compared with 20% of placebo-treated patients. At Month 42, 53% of patients on continuous acoramidis maintained that level of improvement. In a more conservative analysis, improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month

BridgeBio's acoramidis shows cardiac reversal data at ESC 2026

Mon, 31 Aug 2026 06:04:00 -0400

BridgeBio Pharma (Nasdaq: BBIO) presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2026, according to a company statement.
Data from a cardiac magnetic resonance imaging (CMR) substudy showed that 54% of acoramidis-treated patients demonstrated clinically meaningful improvement in left ventricular systolic function at Month 30, compared with 20% of placebo-treated patients. At Month 42, 53% of patients on continuous acoramidis maintained that level of improvement. In a more conservative analysis, improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Sun, 30 Aug 2026 10:00:00 -0400

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis

- Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients

- Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the European Journal

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Sun, 30 Aug 2026 10:00:00 -0400

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis

- Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients

- Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the European Journal

BridgeBio doses first patient in Phase 3b/4 acoramidis heart study

Wed, 26 Aug 2026 07:33:06 -0400

BridgeBio Pharma (Nasdaq: BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on cardiac structure, function, and amyloid burden in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
ASCEND-ATTR is a single-arm, prospective, open-label study designed to enroll approximately 150 participants. Cardiovascular magnetic resonance (CMR) imaging and cardiac echocardiography will be conducted annually over 36 months. The primary efficacy endpoint is responder status at Month 36, based on improvement from baseline in left ventricular systolic function. Secondary endpoints include CMR and echocardiographic measures of cardiac function, structure, and amyloid burden at

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

Wed, 26 Aug 2026 07:30:00 -0400

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients

- ATTR-CM has long been treated as a disease where progression can be slowed, but these findings raise the possibility that acoramidis may be capable of reversing progression and actively restoring heart health. TTR stabilization with acoramidis may allow the body's natural amyloid clearance mechanisms to outpace amyloid formation, thereby enabling cardiac remodeling and functional recovery

- ASCEND-ATTR

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

Wed, 26 Aug 2026 07:30:00 -0400

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients

- ATTR-CM has long been treated as a disease where progression can be slowed, but these findings raise the possibility that acoramidis may be capable of reversing progression and actively restoring heart health. TTR stabilization with acoramidis may allow the body's natural amyloid clearance mechanisms to outpace amyloid formation, thereby enabling cardiac remodeling and functional recovery

- ASCEND-ATTR

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

Mon, 24 Aug 2026 07:30:00 -0400

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

Mon, 24 Aug 2026 07:30:00 -0400

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small

Form 4 BridgeBio Pharma, Inc. For: Aug 18 Filed by: Kumar Neil

Thu, 20 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260820/26956605.html

Form 4 BridgeBio Pharma, Inc. For: Aug 18 Filed by: Kumar Neil

Thu, 20 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260820/26956605.html

Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil

Wed, 19 Aug 2026 16:34:00 -0400
si-local-file:///var/storage/secattach/20260819/26950566.html